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Remodeling of the extracellular matrix (ECM) during development, angiogenesis, wound healing, tumor metastasis, and other
morphogenetic processes depends on the exquisitely regulated activities of matrix metalloproteinases (MMPs). Yet very little is known about
the activity patterns of these proteases in vivo. We have employed fluorescent MMP-substrates, both in vitro and in vivo, to characterize
patterns of MMP activity in the zebrafish embryo. Qualitatively similar patterns of degradation are detected using native Type I or Type IV
collagen substrates, suggesting that multiple MMPs are being regulated concomitantly. MMP activity is observed primarily in ECM-rich
structures predicted to be undergoing active remodeling, such as the perichordal sheath and somite boundaries. Patterns of Type I and Type
IV collagen hydrolysis are similar, but not identical in embryos of any given stage. Conventional gelatin zymography shows MMPs present
in embryos as early as 3-somites (11 h) and our in vivo assays detect Type IV collagen degradation at somite boundaries as early as 4-somites
(11.5 h). However, we are unable to detect significant in vitro activity using homogenates made from embryos prior to Prim-16 (31 h). Mixed
lysate assays demonstrate that this is the result of endogenous inhibitors present in early embryos, suggesting a model of matrix remodeling
regulated by spatially heterogeneous MMP inhibition.
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The extracellular matrix (ECM) is central to the
mechanical and biological characteristics of tissues, and
as such, is of great interest to developmental and cell
biologists. The ECM is composed of a diverse and dynamic
population of large glycoproteins that serve as substrates for
cell adhesion and sources of signaling molecules (reviewed
in Aumailley and Gayraud, 1998; Vu, 2001; Pupa et al.,
2001; Bosman and Stamenkovic, 2003). However, as a
non-living component of tissues, the remodeling of the
ECM during development, angiogenesis, wound healing,
metastasis, or other dynamic process must result from the
actions of cells on the ECM. Although the mechanisms that0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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clear that degradation and re-synthesis of the ECM is a
finely balanced, and therefore tightly controlled process,
and that its misregulation can lead to a plethora of disease
processes (reviewed in Parks and Mecham, 1998; Nagase
and Woessner, 1999; Ramani and McTiernan, 2003; Lee-
man et al., 2003; Visse and Nagase, 2003; Mott and Werb,
2004).
Although most ECM proteins are relatively resistant to
proteolysis, a large and diverse family of primarily zinc-
dependent proteases – the matrix metalloproteinases
(MMPs) – have been shown to act on nearly all components
of the ECM (reviewed in Parks andMecham, 1998; Sternlicht
and Werb, 2001; Visse and Nagase, 2003; Mott and Werb,
2004). All characterizedMMPs share diagnostic catalytic and
pro-domains, and most also share a hemopexin domain that is
thought to mediate their interactions with triple-helical
collagens as well as with important regulatory molecules286 (2005) 405 – 414
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al., 1995). Because precise control of ECM remodeling is
critical to development and tissue homeostasis, MMP
activity is regulated at several levels. In addition to
transcriptional and translational regulation, all known
MMPs are synthesized as inactive pro-enzymes that must
be activated by other regulators, which are frequently
concentrated on the extracellular faces of cell membranes
(reviewed in Seki, 2002). A further level of regulation is
provided by the expression of tissue inhibitors of MMPs
(TIMPs), of which four vertebrate homologues have been
characterized to date (reviewed in Brew et al., 2000;
Baker et al., 2002; Lindsey, 2004). Because the relation-
ship between gene expression and patterns of functional
proteolytic activity is indirect, and due to the overlapping
expression and specificities of individual MMPs, analyses
of MMP expression patterns and the phenotypes of single
gene knock-outs have only provided limited insight into
the roles of MMP activity during development.
Drosophila embryos lacking MMP function develop
normally until metamorphosis (Page-McCaw et al., 2003),
and mouse embryos lacking MMP-2, 3, 7, 9, 11, or 12 show
only subtle developmental defects (reviewed in Sternlicht
and Werb, 2001). Mouse embryos lacking MMP-14 exhibit
craniofacial and other defects resulting from reduced
collagen turnover (Holmbeck et al., 1999), but do survive
postnatally. In contrast, zebrafish embryos lacking MMP-2,
MMP-14, or TIMP-2 develop with severe morphological
abnormalities and are not viable (Zhang et al., 2003a,b,c).
Moreover, pharmacological inhibitors of MMP activity have
been shown to profoundly affect development in species
ranging from cnidarians to mammals (Leontovich et al.,
2000; Solberg et al., 2003). The existence of dozens of
MMPs with overlapping specificities participating in a
complex post-translational regulatory network may explain
this apparent paradox. Significant redundancy exists
between MMPs, and feedback mechanisms within the
regulatory system may serve to compensate for the loss of
individual MMPs during the extended development of
mammalian embryos. Although the patterns of, and require-
ments for, MMP gene expression are informative, know-
ledge of the patterns of MMP activity at high spatial and
temporal resolution may provide more insight into the roles
of matrix remodeling and its regulation in vertebrate
embryonic development.
Rather than dissecting the molecular roles of individual
MMPs from the bottom up – one gene product at a time –
we have undertaken to characterize the overall patterns of
ECM remodeling in the developing embryo. Using this
Ftop–down_ approach, we hope to determine when and
where MMPs are active, and on what kinds of substrates.
These data will allow us to constrain the questions of
what molecules may be responsible for these patterns, and
how these activities may be regulated. We have employed
a novel approach to assay MMP activity in vivo that is
based on the injection, and in situ degradation, of heavilyfluoresceinated native collagens. These substrates, devel-
oped for in vitro assays of MMP activity, are only weakly
fluorescent in their native state due to intramolecular
quenching. However, when proteolytically degraded, the
quenching is relieved, resulting in an increase in
fluorescent signal. Owing to the transparency of the
zebrafish embryo, and the high spatial resolution and
sensitivity of confocal microscopy, we are able to detect
the degradation of these substrates in the living embryo.
This technique may accurately be described as in vivo
zymography.
Using native fibrillar (Type I) and basement membrane
(Type IV) collagens as substrates, and assessing their
degradation in different regions of the embryo during
development, we have compiled what we believe to be the
first description of MMP activity patterns in an intact
organism. These patterns are consistent with predicted
locations of ECM remodeling. Conventional gelatin zymog-
raphy of zebrafish embryo lysates confirms the dynamic
expression of MMPs during their development. Finally, our
observations of MMP activity in zebrafish embryonic
lysates suggest that spatially constrained inhibition of
MMP activity plays a fundamental role in regulating
patterns of MMP activity during embryogenesis.Materials and methods
Fish maintenance, embryo collection
Wild-type breeding adult zebrafish were maintained as
outlined in Westerfield (1995) and embryos were collected
by natural spawning over marbles. When necessary,
embryos were manually dechorionated under a dissecting
microscope using fine forceps.
In vitro MMP assays
Lysates were made by collecting 50 embryos of a given
stage in a 1.5-ml microcentrifuge tube, rinsing in fresh
embryo medium (Westerfield, 1995), settling on ice,
removing excess media, suspending in 10 Al ice-cold lysis
buffer/embryo (150 mM NaCl, 10 mM HEPES, 2 mM
DTT, 0.1% Triton X-100, pH 8.0), grinding with a tight-
fitting pestle, and flash freezing in liquid nitrogen. Frozen
lysates were stored at 80-C, thawed and spun at 14000
rpm in a cold centrifuge to remove insoluble debris just
prior to use.
Chambers of a 96-well plate were loaded with 50 Al
lysate [or 0–1.0 U/ml Clostridium histolyticum collagenase
(Sigma)], GM6001 (Chemicon) to give a final concentration
of between 0 and 100 mM, lysis buffer to bring the volume
to 190 Al, and, lastly, 10 Al of 1 mg/ml fluoresceinated
collagen substrate (Type I or Type IV) (Molecular Probes) in
lysis buffer. FITC fluorescence was measured every 5 min
for 2 h at 28.5-C using a Molecular Devices fMax
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triplicate, and background fluorescence measured in wells
containing substrate without lysate or collagenase was
subtracted. Data are reported as % increase above this
background with error bars representing standard deviations
of these means.
Gel zymography
1D gel zymography was performed using lysates
prepared as described above, with the exception that they
were stored in lN2. Lysates were mixed with 5 non-
reducing SDS-PAGE sample buffer, and run on 10%
polyacrylamide gels with 1% gelatin. After separation,
proteins were renatured by incubating gels in two changes
of 2.5% Triton X-100 for 30 min, then shifted to
zymography developing buffer (50 mM Tris–HCl pH 7.5,
5 mM CaCl2, 1 mM ZnSO4, 2.5% Triton X-100), and
incubated at room temperature for 60 h with gentle agitation
before staining.
MMP-substrate/dextran/collagen injections
Embryos were dechorionated at various stages, and
transferred to 3% methylcellulose in embryo medium,
where they were injected with a mixture of 1 mg/ml
fluoresceinated collagen (Type I or Type IV) substrate and
1 mg/ml rhodamine-conjugated 70 kDa dextran dissolved
in Danieau Buffer [58 mM NaCl, 0.7 mM KCl, 0.4 mM
MgSO4, 0.6 mM Ca(NO3)2, 5 mM HEPES, pH 7.6].
Injections were targeted to either the developing head or
the tails of embryos, and an effort was made to do as little
tissue damage as possible during the procedure. Injected
embryos were either mounted for immediate viewing, or
allowed to recover for 1 h in fresh embryo medium, and
then fixed in 4% paraformaldehyde for later imaging.
Microscopy was performed using a Leica SP-2 confocal
microscope fitted with 20 (0.7 NA) water immersion
lens.
Control embryos were injected with the following
variations: To control for heterogeneity in substrate degra-
dation product localization within the embryo, the mixture to
be injected was pre-treated with collagenase (1 U/ml) for 1 h.
To verify the MMP-dependence of observed degradation,
embryos were either co-injected with GM6001(4 Ag/ml)
(10 nM), or pre-injected with this MMP inhibitor, allowed
to recover for 30 min, and then injected with the standard
MMP-substrate/dextran mixtures. To control for heteroge-
neous localization of collagen substrates, embryos were co-
injected with the Type I collagen MMP-substrate and Alexa-
568-conjugated Type I collagen (Chemicon) at identical
concentrations (1 mg/ml). Finally, as a control for ECM
specificity of the detected activity, embryos were co-
injected with Type IV MMP-substrate and the more generic
red fluorescent protease substrate DQ-BODIPY-casein
(Molecular Probes).Image processing
All microscopic images were processed using ImageJ
(http://rsb.info.nih.gov/ij/; Abramoff and Magalhaes, 2004)
and/or Photoshop 7.0 (Adobe). Image processing consisted
of projection of confocal stacks, combination of fluorescent
channels, rotation, gamma-adjustment, and assembly and
labeling of plates. Where gamma-adjustments were made,
comparable images were adjusted identically.Results and discussion
In vitro MMP assays
We investigated the use of heavily fluoresceinated native
collagens as substrates for zebrafish MMPs. To verify the
ability of this assay to detect degradation of these substrates,
and to assess the relationship of fluorescent signal strength
to enzymatic activity, we measured the fluorescence of
substrates treated with known concentrations of collagenase.
Signal strength varies linearly (R2 = 0.95) with enzyme
activity over a range of 0.05–1.0 U/ml, resulting in an
approximately 64% increase in fluorescent intensity per unit
of enzyme activity after a 2-h incubation (Fig. 1A). When
whole 36-h embryo lysates are used in this assay, detectable
substrate degradation is blocked by nanomolar concentra-
tions of the MMP inhibitor, GM6001 (a.k.a. Ilomastat or
Galardin) (Fig. 1B). GM6001 functions by chelating the
catalytic zinc ion in MMPs, and is reported to specifically
inhibit MMPs at the concentrations employed (Grobelny
et al., 1992; Whittaker et al., 1999; Santiskulvong and
Rozengurt, 2003); thus, it appears that the fluorescent signal
is not a result of general proteolysis, but is rather an MMP-
dependent phenomenon.
This in vitro analysis reveals negligible activity versus
either Type I or Type IV collagen substrates in lysates made
from embryos prior to the primordia stages of development
(i.e., prior to about 24 h) (Figs. 1C and D). This is
unexpected given the prediction that ECM remodeling will
be important in morphogenesis, which is obviously occur-
ring prior to stages where MMP activity is detected using
this assay. Furthermore, this is inconsistent with our
observations of extensive MMP activity in earlier stages
using in vivo assays (described below and in Figs. 4 and 5),
and with the presence of gelatinolytic activity in zymo-
graphs of lysates made from embryos as early as 3-somites
(11 h) (Fig. 3). One explanation for this inconsistency is that
the level of activity in early embryos is below the limits of
detection by this assay. Alternatively, endogenous inhibitors
of MMPs may be abundant (and spatially restricted) in early
embryos, and the preparation of embryo lysates therefore
results in homogenates that include sufficient inhibitors to
block the activity of any MMPs that are present.
To distinguish between these possibilities, we tested 48-h
lysates (in which significant activity was detected; Fig. 1D)
Fig. 1. In vitro MMP assays. All data represent fluorescence generated over 2 h at 28.5-C. (A) Type IV substrate incubated with known concentrations of C.
histolyticum collagenase results in a fluorescent signal proportional to the concentration of enzyme used. Approximately 64% increase over background
fluorescence is observed per unit of collagenase in 2 h. (B) The MMP inhibitor GM6001 effectively inhibits the degradation of either Type I or Type IV
substrates by 36-h lysates. Degradation of Type I (C) and Type IV (D) substrates by staged embryo lysates shows increasing activity with age. Significant
activity is not detected prior to Fprimordium_ stages (24 h).
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no significant activity was detected; Fig. 1D). If the lack of
detectable activity in 18-h lysate is due to the presence of
endogenous inhibitors, the addition of 18-h lysate to 48-h
lysate may be expected to reduce the activity of the mixed
lysate relative to an equivalent volume of reaction buffer.
Alternatively, if there is simply a low level of MMP activity
in the 18-h lysates, no significant change in fluorescence per
unit 48-h lysate should be observed. Not only do the mixed
lysates show significantly reduced activity as more 18-h
lysate is added, simply diluting 48-h lysate increases the
activity observed per unit lysate (Fig. 2). These data indicate
the presence of endogenous inhibitors at both stages, with
relatively greater abundance in the 18-h lysate. Thus, the
lack of detectable MMP activity in the 18-h lysate (and,
presumably, in lysates of other pre-primordium stages) is
due to a relative excess of endogenous inhibitors, rather than
a lack of MMPs.
Gelatin zymography
Consistent with this, we observe bands of gelatinolytic
activity when lysates of embryos as early as 3-somites (11 h)are subjected to conventional gelatin zymography (Fig. 3).
We cannot detect the primary MMP-2 and MMP-9 bands
(62 and 92 kDa, respectively) due to abundant yolk proteins
with similar mobilities; however, high molecular weight
complexes of MMPs are detectable starting at 3-somites
(11 h) and later in development. The mobility of this high
molecular weight complex increases with developmental
time, suggesting a change in its molecular composition
(Fig. 3).
Thus, the enzymatic capacity to degrade collagen is
present in embryos from early developmental stages
onwards; however, it is inhibited in homogenates by the
relative abundance of inhibitors. Of the endogenous
inhibitors of MMPs, only TIMP-2 has been characterized
in zebrafish. It is expressed from fertilization through to at
least 48 h, and its mis-expression results in severe
developmental abnormalities (Zhang et al., 2003a). These
data, in addition to the existence of other uncharacterized
TIMPs in the sequence database, suggest that expression of
these endogenous inhibitors may spatially restrict MMP
activity during zebrafish development. Consequently, we do
not suggest that the in vitro MMP activity profiles of whole
embryo lysates shown in Figs. 1C and D are representative
Fig. 3. Gelatin zymography of staged embryo lysates. Lysates of 1-cell,
sphere (4 h), 50% epiboly (5.3 h), 3-somites (11 h), 18-somites (18 h), and
Primordium-5 (24 h) embryos were subjected to conventional gelatin
zymography on a 10% PAGE gel with 1% gelatin. MMP activity results in
negatively stained bands. Mobility of molecular weight standards are shown
on the left, and zymography standards including high-molecular weight
complexes, activated and pro-forms of MMP-2 and 9 on the right. MMPs in
high molecular weight complexes appear in lysates of 3-somite (11 h)
embryos, and remain detectable through prim-5 (24 h). Abundant yolk
proteins (dark bands between 50 and 100 kDa) in these lysates obscure
uncomplexed MMP-2/9 activity that may also be present in these lysates.
Fig. 2. Dilution of 48-h lysate suggests a role for inhibitors. 48-h lysates
were diluted using either reaction buffer (circles) or 18 h lysates (triangles)
and incubated for 2 h with Type IV substrate. The resulting background-
subtracted fluorescence values were then normalized with respect to the
amount of 48-h lysate used (i.e., for assays using 50 Al of undiluted 48-h
lysate, the background-subtracted fluorescence was divided by 50, for
assays using 25-Al, 48-h lysate diluted with either 25-Al reaction buffer or
18-h lysate, the background-subtracted fluorescence was divided by 25).
The values therefore represent activity per microliter of 48-h lysate. When
diluted with reaction buffer, the activity per unit 48-h lysate increases
(circles), suggesting that the 48-h lysates do contain endogenous inhibitors,
but at relatively low concentrations. In contrast, when diluted with 18-h
lysates, the activity per unit 48-h lysate decreases (triangles). This suggests
the presence of relatively abundant inhibitors in the 18-h lysates, explaining
their lack of activity in the in vitro assays shown in Fig. 1.
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represent the relative abundances of activated MMPs and
inhibitors present in embryos at this time. In order to
investigate the spatial distribution of MMP activity in
developing embryos, we injected substrates into developing
embryos and observed the resulting patterns of fluorescence
in situ.
In vivo MMP assays
Native collagens are relatively resistant to most pro-
teases, and since the fluorescence generated by these
substrates in vitro is reduced to background levels by
nanomolar concentrations of the metalloproteinase inhibitor
GM6001, we are confident that the fluorescence detected in
these assays is indicative of MMP activity. We observed the
degradation of these substrates under various conditions in
18-somite zebrafish embryos to test several predictions.
First, that a specific pattern of fluorescence will be
generated by the spatially heterogeneous degradation of
these MMP-substrates. Second, that degradation will be
most prominent in regions of the embryo where ECM
remodeling is likely occurring (e.g., at somite boundaries
during somite morphogenesis, and the notochord sheath
during the straightening and elongation of the body axis).
Third, any pattern observed will depend on the spatial
heterogeneity of substrate breakdown (i.e., injection of pre-
digested substrates will not result in heterogeneous binding
of the degradation products). Fourth, MMP inhibitors (suchas GM6001) will either abolish or significantly inhibit the
degradation of these substrates. Fifth, the pattern of
substrate degradation will be distinct from the pattern of
dispersal of injected collagen (e.g., as detected by injecting
constitutively fluorescent collagen). Lastly, the pattern of
substrate degradation will be distinct from the pattern of
degradation observed for a more generic protease substrate.
All of these predictions are supported (Fig. 4). Embryos
co-injected with 70 kDa rhodamine dextran and either Type
I or Type IV quenched FITC-substrates (Figs. 4A and C,
respectively) show widely distributed rhodamine fluores-
cence (red), showing that the injected material has unim-
peded access to extracellular spaces throughout an extensive
region of the embryo. In contrast, FITC fluorescence (green)
is largely restricted to somite boundaries, the perichordal
sheath (not shown), interstitial spaces surrounding the gut
and pronephros, and the basement membrane separating the
ectoderm from the mesoderm in the tail. However, when the
injected quenched FITC-substrates are pre-treated with
collagenase, this spatial restriction of FITC-fluorescence is
lost, resulting in a diffuse pattern of fluorescence similar to
that seen with the rhodamine dextran (Fig. 4E). This
demonstrates that the observed patterns of FITC fluores-
cence in Figs. 4A and C are not a function of collagen
breakdown products being specifically localized after
proteolysis. When these substrates are co-injected with
GM6001, the patterns of FITC fluorescence are significantly
reduced except in the immediate vicinity of the injection
site, suggesting that the inhibitor diffuses more rapidly than
the native collagen substrates (Figs. 4B and D). Consistent
Fig. 4. The dequenching of fluorescence following injection of substrate reveals spatial patterns of MMP activity. All images are of the trunk/tail of 18 S (18 h)
embryos that were injected with the indicated mixture, incubated for 1 h, then fixed and visualized by confocal microscopy. Long arrows indicate site of
injection where applicable. Projected stacks are shown, with anterior to the left and dorsal up with the exception of panel G, which is a dorsal view with anterior
to the right, and panels H and J which are a single focal planes. In all panels, a merge of red and green channels is shown, with the red and green channels
shown separately in the next panels, respectively (i.e., panel A red/green merge, panel AV red, panel AW green). (A) Injection with Type I substrate, rhodamine
dextran, and DMSO (1:25) results in ubiquitous rhodamine fluorescence (red) and FITC fluorescence constrained to somite boundaries (arrow heads), basement
membrane (short arrow), and perichordal sheath (not visible in this projection) throughout the region of the embryo accessed by the injected material. (B)
Injection with Type I substrate, rhodamine dextran, and GM6001 (1:25) results in significant reduction of substrate degradation except near the site of injection.
(C) Injection with Type IV substrate, rhodamine dextran, and DMSO (1:25) results in fluorescence similar to that seen in panel A. (D) Injection with Type IV
substrate, rhodamine dextran, and GM6001 (1:25) results in inhibition of substrate degradation except near the site of injection. (E) Injection of Type IV
substrate and rhodamine dextran after 1-h pre-digestion with 1 U/ml collagenase results in loss of spatial patterning of FITC fluorescence, showing that
patterning is dependent on spatially regulated degradation of substrate. (F) Injection of embryos with GM6001 30 min prior to injection with Type IV substrate
and rhodamine dextran results in complete loss of FITC fluorescence, showing that inhibition of MMPs blocks degradation of this substrate. (G) Co-injection of
constitutively fluorescent Alexa-568-conjugated Type I collagen (red) and quenched FITC-conjugated Type I collagen (green) (both at 1 mg/ml) shows
restricted degradation of the intramolecularly quenched MMP-substrate and extensive distribution of the injected collagens. (H) High-magnification view of a
single optical section through the somitic mesoderm of an embryo injected with the mixture described in panel G showing collagen fluorescence (red) within
somites and in the interstitial spaces of the visceral mesoderm, while collagen degradation (green) is restricted to somite boundaries and the space surrounding
the developing gut. (I) High-magnification view of the posterior end of the notochord in an embryo injected with the mixture described in panel G showing
collagen fluorescence (red) interstitially throughout the mesoderm, and collagen degradation (green) restricted to the perichordal sheath and a few cells in the
ventral mesoderm. (J) High-magnification view of the trunk of an embryo co-injected with Type IV quenched FITC MMP-substrate (green) and similarly
quenched BODIPY-casein protease substrate (red) showing widespread protease activity and restricted MMP activity.
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FITC fluorescence is completely abolished (Fig. 4F). At the
concentrations used, it is unlikely that this inhibitor is
having a significant effect on ADAMs or other proteases.
As a more rigorous control to eliminate the possibility
that these patterns are simply a function of substrate
localization, we conjugated Type I collagen with Alexa-
568, and co-injected it with the quenched FITC-conjugated
Type I collagen substrate (Figs. 4G–I). In these embryos,
Alexa-568 fluorescence (red) was widely distributed
throughout the embryo, showing that injected Type I
collagen has access to interstitial spaces within the tissues
of the embryo. FITC fluorescence (green) was restricted as
described above, showing that injected collagen is only
being degraded in some of the extracellular spaces to which
it has access. Finally, we co-injected quenched FITC-
conjugated Type IV collagen with quenched BODIPY-
conjugated casein, which is a substrate for a wider spectrum
of proteases. In these embryos, FITC fluorescence (green)
was observed as previously described, but BODIPY
fluorescence (red) was more widely distributed, consistent
with the collagen degradation being MMP-dependent, rather
than an indication of general proteolysis (Fig. 4J).
Taken together, these data suggest that the pattern of
FITC fluorescence after injection of Type I or Type IV
collagen substrates is representative of the patterns of
activated MMPs capable of degrading these substrates in
vivo. We have therefore undertaken a preliminary character-
ization of the ontogeny of MMP activity in the developing
embryo using this assay.
Patterns of collagen degradation during development
Embryos of various stages were co-injected with 70 kDa
rhodamine dextran and either Type I or Type IV MMP-
substrate, incubated for 1 h, then fixed and imaged by
confocal microscopy (Fig. 5). Both substrates are degraded
more extensively in older embryos. Type IV collagen
degradation is detected at somite boundaries as early as 4
S (11.5 h) (Figs. 5C and D), whereas we did not detect Type
I collagen degradation at this stage (Figs. 5A and B).
However, the patterns of dequenching are broadly similar
for both substrates: Both types of collagen appear to be
degraded in the perichordal sheath during notochord
elongation, and at maturing somite boundaries. Some
differences are apparent upon closer examination: relatively
less signal is observed at somite boundaries and in the lens
capsule in embryos injected with Type IV collagen than
with Type I collagen (compare Figs. 5F and H, and M and
O, respectively). Conversely, Type IV collagen appears to
be more rapidly degraded in early embryos, and at the
interface between ectoderm and mesoderm in the tail
(compare Figs. 5A and C, N and P, respectively).
It is likely that that these patterns of fluorescence
represent genuine MMP-dependent degradation of these
collagen substrates, but because the substrates themselveshave been injected into the tissues of the embryo, we cannot
conclude that these patterns of ECM degradation are
normally occurring in the embryo. That is, while the
capacity for degradation of Type I collagen (for example)
clearly exists at somite boundaries in 18 S embryos (Fig.
5J), we do not know that Type I collagen is present in the
endogenous ECM at this location. Thus, without more
detailed knowledge of the nature of the ECM in the
developing fish embryo, we can interpret these data only
as evidence for specific patterns of degradative capacities.
Furthermore, because both Type I and Type IV collagens are
substrates for several different MMPs (reviewed in Whit-
taker and Ayscough, 2001), we cannot determine from our
data which enzyme(s) are responsible for the proteolytic
activity detected. Nonetheless, we can draw some important
conclusions from these observations.
Extensive MMP activation has occurred in embryos by
mid-somitogenesis (inconsistent with MMP activity meas-
urements of homogenates, as discussed above), and these
activities are spatially constrained to regions of the embryo
where significant ECM deposition has or is occurring (the
perichordal sheath, somite boundaries, surrounding the
developing pronephros and in the head mesenchyme)
(Crawford et al., 2003). Furthermore, because both Type I
and Type IV collagens are broken down in these spaces, it
seems likely that a constellation of MMPs are being
regulated in concert. In principle, either MMP-2 or MMP-
13 could be solely responsible for the degradation of both of
these substrates, as these enzymes are both thought to
hydrolyze both of these collagens (reviewed in Whittaker
and Ayscough, 2001). Despite the parsimony of this idea,
we do not think a single enzyme is likely responsible for the
observed degradation of these substrates, as many MMPs
(including MMP-2, 9, 14, 15, 23, 25, and probably others)
are expressed during the developmental stages examined
(Zhang et al., 2003b,c; our unpublished observations). Thus,
several MMPs may be regulated concomitantly, most
probably by the spatially restricted activity of TIMPs.
TIMPs have been characterized as acting as promiscuous
MMP inhibitors (Brew et al., 2000), and since endogenous
inhibitors of MMPs likely play a fundamental role in the
spatial regulation of MMP activity (Fig. 2), we suggest that
much of this spatial regulation occurs at the level of MMP
inhibition by TIMPs.
Although TIMPs are concentrated in ECM-rich environ-
ments like the perichordal sheath (Zhang et al., 2003a), they
may be less effective at inhibiting MMPs in these locations
due to their competing interactions with ECM components
(Leco et al., 1993; Klenotic et al., 2004) than they are in
ECM-poor environments. Consequently, relatively ubiqui-
tous expression of TIMPs may result in a pattern of protein
accumulation that, counterintuitively, mirrors that of MMP
activity. Such a system would result in a feedback-inhibition
mechanism as ECM degradation releases these MMP
inhibitors from their ECM-bound reservoirs. This would
allow constant remodeling of ECM-rich structures such as
Fig. 5. Patterns of Type I and Type IV collagen degradation during development. Embryos were injected with either Type I (A, B, E, F, I, J, M, and N) or Type
IV (C, D, G, H, K, L, O, and P) substrates mixed with rhodamine dextran at 4 S (11.5 h) (A–D), 12 S (15 h) (E–H), 18 S (18 h) (I–L), or Prim-5 (24 h)
(M–P), incubated for 1 h, and then fixed. Confocal projections showing fluorescence of rhodamine (red) and FITC (green) in lateral views (A, C, I–L, N–P),
dorsal views (F and H), or anterior views (E, G, and M) are shown. Breakdown of Type IV substrate is apparent at somite boundaries as early as 4 S (11.5 h)
(C and D, arrowheads), and both substrates are broken down at somite boundaries (arrowheads) and in the perichordal sheath (arrows) by 12 S (15 h) (F and H).
At 18 S (18 h), degradation of both substrates is detected in the perichordal sheath (arrows) and at somite boundaries (arrowheads) (J and L). Type I, but not
Type IV, substrate degradation is apparent in the lens capsule (arrows) (I and K, respectively). This pattern persists in the Prim-5 (24 h) embryo, with Type I, but
not Type IV, substrate degradation detected surrounding the lens (arrows) (M and O). Both substrates continue to be degraded at maturing somite boundaries
(white arrowheads), in the perichordal sheath (arrow) and in the basement membrane separating the mesoderm from the ectoderm in the tail (black arrowheads),
but Type IV substrate degradation is more prominent at this latter location (N and P).
B.D. Crawford, D.B. Pilgrim / Developmental Biology 286 (2005) 405–414412somite boundaries while allowing them to retain their
mechanical and adhesive properties. Consistent with this
model, immunological and fluorescent reporter-based local-
ization of TIMPs in zebrafish and other organisms reveal
them to accumulate in ECM-rich locations such as somite
boundaries and the perichordal sheath (Robinson et al.,
2001; Zhang et al., 2003a). As further support for this
model, although MMP-2 and TIMP-2 are expressed
ubiquitously throughout early development (Zhang et al.,
2003a,c), we do not detect MMP activity in vivo until early
somitogenesis. This activity is detected concomitantly with
the deposition of ECM at somite boundaries (Crawford et
al., 2003) and shortly after the earliest reported expression
of collagen mRNAs (Yan et al., 1995; Morvan-Dubois et al.,
2002; Haftek et al., 2003). Moreover, embryos injected with
the MMP inhibitor GM6001 at sphere stage (4 h) do not
show abnormalities until after the onset of somitogenesis(data not shown), suggesting that ECM remodeling is not
significant prior to this stage. Thus, we suggest that the
presence of ECM may be required to mediate the de-
repression of MMP activity. The absence of detectable
MMP activity in early embryos may be due to TIMPs being
free to inhibit MMPs until significant ECM deposition (with
TIMP-binding capacity) begins during somitogenesis.Conclusions
MMP-mediated matrix remodeling is implicated in a
bewildering variety of physiological and disease processes
including arthritis, tumor metastasis, angiogenesis, skeletal
development and degeneration, tooth development and
wound healing, as well as normal tissue homeostasis and
development. Our understanding of the cell biology of
B.D. Crawford, D.B. Pilgrim / Developmental Biology 286 (2005) 405–414 413MMP activity and regulation has been advancing rapidly,
with a significant body of research published in the last few
years. Yet, the roles of MMP activity in embryonic
development are still poorly understood and investigation
of these roles has been hampered by the lack of a good
model system.
Recent efforts to develop in vivo assays for MMP
activity based on near infrared fluorescence detection of a
synthetic substrate have suggested an important role for
MMP-2 in a mouse model of HT1080 human fibrosarco-
mas, and has demonstrated the efficacy of AG3340
(prinomastat) at inhibiting this MMP (Bremer et al.,
2001). The in vivo assays described here differ from these
in the use of native collagens, rather than synthetic
polymers, as substrates, detection by confocal microscopy,
allowing significantly higher resolution and sensitivity,
more rapid detection, and detection in the context of intact
developing embryos. This assay could be easily adapted to
take advantage of fluorogenic substrates that are acted upon
by more specific ranges of MMPs (Bremer et al., 2001;
McIntyre et al., 2004), and/or combined with more specific
pharmacological inhibitors of MMPs (Brown et al., 2004)
and/or morpholino gene knock-downs to elucidate the
specific molecules responsible for various components of
the observed patterns. Currently, Type I and Type IV
collagens are the only ECM components readily available as
heavily fluoresceinated native proteins. As is shown here,
significant progress can be made with these alone; however,
as more protein conjugates become available, experiments
with more precision and specificity will become feasible.
Furthermore, in combination with the growing array of
disease models available in fish, and the thousands of
developmental mutations, this potentially represents a
valuable in vivo tool for the investigation of the functional
contribution of MMPs in a variety of normal and idiopathic
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